Health Wegovy and co. bring many benefits and some risks, according to study
Many benefits - but also some risks: In a systematic analysis, researchers have used huge data sets to determine the medical advantages and disadvantages of weight loss injections such as Wegovy and similar drugs.
20.01.2025, 17:00
SDA
According to the study, Wegovy and other GLP-1 receptor agonists (GLP-1-RA) reduce the likelihood of heart attack, stroke, dementia, psychosis and addiction, among other things. On the other hand, they are associated with increased risks of gastrointestinal problems and joint inflammation, writes the team led by Ziyad Al-Aly from Washington University in St. Louis in the journal "Nature Medicine".
"These large data sets underline the positive risk-benefit balance of these preparations," says gastroenterologist Frank Tacke from the Charité hospital in Berlin, who was not involved in the study. "That is reassuring for the time being."
In Switzerland, Wegovy has been approved for people who are severely or very severely overweight since 2022. The health insurance company covers the costs.
